Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda

HIV Medicine

Volumn 13, Issue 3, 2012, Pages 166-171

  Asiimwe, F M ^a   Moore, D M ^a,b,c   Were, W ^a   Nakityo, R ^a   Campbell, J ^d   Barasa, A ^a   Mermin, J ^a   Kaharuza, F ^a  

^a CDC Uganda   (Uganda)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d US CDC   (Uganda)

Author keywords

Highly active antiretroviral therapy; HIV; Kaposi's sarcoma; Mortality; Sub Saharan Africa; Uganda

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ADULT; ARTICLE; BODY MASS; CANCER REGRESSION; CD4 LYMPHOCYTE COUNT; DEATH; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SEX; TREATMENT OUTCOME; UGANDA; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; SARCOMA, KAPOSI; TREATMENT OUTCOME; UGANDA; VIRAL LOAD;

EID: 84856564218     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2011.00955.x     Document Type: Article

References (19)

1. Dal Maso L, Serraino D, Franceschi S. Epidemiology of AIDS-related tumours in developed and developing countries. Eur J Cancer 2001; 37: 1188-1201.
2. Newton R, Ziegler J, Bourboulia D etal. The sero-epidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in adults with cancer in Uganda. Int J Cancer 2003; 103: 226-232.
3. Hladik W, Dollard SC, Downing RG etal. Kaposi's sarcoma in Uganda: risk factors for human herpesvirus 8 infection among blood donors. J Acquir Immune Defic Syndr 2003; 33: 206-210.
4. Wabinga HR, Parkin DM, Wabwire-Mangen F, Mugerwa JW. Cancer in Kampala, Uganda, in 1989-91: changes in incidence in the era of AIDS. Int J Cancer 1993; 54: 26-36.
5. Parkin DM, Wabinga H, Nambooze S, Wabwire-Mangen F. AIDS-related cancers in Africa: maturation of the epidemic in Uganda. AIDS 1999; 13: 2563-2570.
6. Kagu MB, Nggada HA, Garandawa HI, Askira BH, Durosinmi MA. AIDS-associated Kaposi's sarcoma in Northeastern Nigeria. Singapore Med J 2006; 47: 1069-1074.
7. Campbell TB, Borok M, Gwanzura L etal. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS 2000; 14: 2109-2116.
8. Rabkin CS, Testa MA, Huang J, Von Roenn JH. Kaposi's sarcoma and non-Hodgkin's lymphoma incidence trends in AIDS Clinical Trial Group study participants. J Acquir Immune Defic Syndr 1999; 21 (Suppl 1): S31-S33.
9. Dupont C, Vasseur E, Beauchet A etal. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. CISIH 92. Centre d'information et de soins de l'immunodeficience humaine. AIDS 2000; 14: 987-993.
10. Dupin N, Rubin De Cervens V, Gorin I etal. The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma. Br J Dermatol 1999; 140: 875-881.
11. Mermin J, Ekwaru J, Were W etal. Utility of routine viral load, CD4 cell count, and clinical monitoring among HIV-infected adults receiving antiretroviral therapy in Uganda: a randomized trial. BMJ 2011; 343: d6792.
12. Chu KM, Mahlangeni G, Swannet S, Ford NP, Boulle A, Van Cutsem G. AIDS-associated Kaposi's sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South Africa. J Int AIDS Soc 2010; 13: 23.
13. Cattelan AM, Calabro ML, Aversa SM etal. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: biological correlates of clinical outcome. Eur J Cancer 1999; 35: 1809-1815.
14. Cattelan AM, Calabro ML, De Rossi A etal. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy. Int J Oncol 2005; 27: 779-785.
15. Pellet C, Chevret S, Blum L etal. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J Invest Dermatol 2001; 117: 858-863.
16. Sgadari C, Barillari G, Toschi E etal. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002; 8: 225-232.
17. Lebbe C, Blum L, Pellet C etal. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998; 12: F45-F49.
18. Grabar S, Abraham B, Mahamat A, Del Giudice P, Rosenthal E, Costagliola D. Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement. J Clin Oncol 2006; 24: 3408-3414.
19. Portsmouth S, Stebbing J, Gill J etal. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS 2003; 17: F17-F22.